Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4482 (Lagevrio) in Healthy Participants Inoculated with Influenza
NCT05818124Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2023
- Primary completion
- Jun 2024
- Modality
- RNA-Targeting Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of molnupiravir in influenza (5 arms), sponsored by Merck & Co. Primary endpoints: Part 1: Infectivity Rate Based on Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR) From Day 1 PM Through Day 8 AM, Part 2: Peak Viral Load (PVL) Determined by Quantitative Viral Culture Tissue Culture Infective Dose 50% (TCID50) Assay From Day 1 PM Through Day 8 AM After Intranasal Inoculation (Molnupiravir PEP… and 2 more. Started Aug 2023; status: completed.
02
Drugs
molnupiravir
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05818124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05818124.